Sinopharm

Sinopharm is a leading pharmaceutical and healthcare group in China, operating under the State-Owned Assets Supervision and Administration Commission of the State Council (SASAC). Established in 2015, the company is primarily engaged in pharmaceutical distribution, scientific research, and the manufacturing of medical and biotech products. With 16 wholly-owned subsidiaries and holding companies, as well as multiple listed entities, including Sinopharm Group Co., Ltd., China National Medicines Co., Ltd. (CNCM), Beijing Tiantan Biological Products Co., Ltd. (TiantanBio), Shyndec Pharmaceutical Co., Ltd. (Shyndec), and Shenzhen Accord Pharmaceutical Co., Ltd. (Accord), Sinopharm has established itself as a key player in the industry. In 2009, the company recorded a revenue of 65 billion Yuan, ranking 50th among central enterprises in terms of revenue and 38th in total profit. The anticipated revenue for 2010 is 80 billion Yuan. Notably, Sinopharm received a CNY300.00M Series B investment on 26 April 2019, with participation from Galaxy Yuanhui Investment, Ample Harvest Finance, ShenZhen GTJA Investment Group, V-Capital, and Frontline BioVentures. With its significant market presence and strategic investments, Sinopharm continues to solidify its position within the pharmaceutical and retail sectors.